Here's Exactly Why Wall Street Thinks Intuitive Surgical Stock Could Soar 102% Over the Next 12 Months
2026-07-28 11:30
•Justin Pope •The Motley Fool
•• • Axe Capital view
Is Intuitive Surgical’s Drop a Doorway for Investors?
Intuitive Surgical’s sharp pullback has pushed valuation to a rare discount, but is it a smart buy for local investors?
Intuitive Surgical (ISRG) has tumbled 44% from its peak, yet Wall Street remains bullish, with most analysts seeing upside of around 100%. The catch is valuation—trading at 38-39 times earnings compared to its usual 65 times. This drop isn’t because fundamentals are crumbling; the company’s da Vinci 5 robotic surgery system is gaining traction in hospitals worldwide, and its recurring revenue from parts and service yields fat gross margins above 66%. For South African investors, ISRG’s story connects loosely. The local healthcare sector isn’t directly exposed to robotics surgery innovation, but this global trend might influence patient care costs and private hospital shares over time. More directly, the USD/ZAR rate matters: a weaker rand boosts the cost of importing such advanced med-tech. If the rand strengthens or global medical device demand slows unexpectedly, this bullish call could falter. Given the valuation discount and growth prospects, it’s worth watching closely but not rushing in just yet—wait for clearer signals or a better entry price. this is just my opinion and not financial advice
Watch USD/ZAR and consider entering on a further dip under 38x earnings if the rand stays stable. Avoid chasing the stock now given limited local sector linkage and high multiples.
- ISRG
- USD/ZAR
- Rand strengthening unexpectedly
- Slower adoption of robotics in healthcare globally
5/10
Intuitive Surgical stock has declined 44% from its highs, but 71% of Wall Street analysts rate it as a buy with price targets suggesting up to 103% upside. The stock's valuation has fallen to 38-39x earnings, well below its historical 64-65x average, while the company's da Vinci 5 robotics platform continues gaining momentum with strong hospital adoption and recurring revenue from parts and services.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Justin Pope
Categories: Equities, Earnings
Tickers: ISRG
Sentiment: Positive - Despite a 44% stock decline, the company maintains market dominance in robotics-assisted surgery with strong fundamentals. The da Vinci 5 is driving adoption and higher utilization rates. The stock's valuation has compressed to 38-39x earnings from historical 64-65x, presenting a buying opportunity. 71% of analysts rate it as a buy with median price target 43% above current price. Recurring revenue model (66%+ gross margins) provides stable growth, with analysts projecting 15-16% annual earnings growth over 3-5 years.
Keywords: Intuitive Surgical, da Vinci 5, robotics-assisted surgery, valuation, analyst price targets, recurring revenue, medical devices
Insights:
- ISRG: Positive: Despite a 44% stock decline, the company maintains market dominance in robotics-assisted surgery with strong fundamentals. The da Vinci 5 is driving adoption and higher utilization rates. The stock's valuation has compressed to 38-39x earnings from historical 64-65x, presenting a buying opportunity. 71% of analysts rate it as a buy with median price target 43% above current price. Recurring revenue model (66%+ gross margins) provides stable growth, with analysts projecting 15-16% annual earnings growth over 3-5 years.